Cargando…

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy

BACKGROUND: In this single-arm phase II study (NCT03557099), we evaluated the efficacy and safety of hetrombopag, a small molecule thrombopoietin (TPO) receptor agonist, in patients with severe aplastic anemia (SAA) who were refractory to standard first-line immunosuppressive therapy (IST). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Guangxin, He, Guangsheng, Chang, Hong, Gao, Sujun, Liu, Xinjian, Chen, Tong, Li, Pei, Han, Bing, Miao, Miao, Ge, Zheng, Ge, Xiaoyan, Li, Fei, Li, Yingmei, Wang, Shunqing, Wang, Yi, Shen, Yaqi, Zhang, Tao, Zou, Jianjun, Zhang, Fengkui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972928/ https://www.ncbi.nlm.nih.gov/pubmed/35371427 http://dx.doi.org/10.1177/20406207221085197

Ejemplares similares

Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study
por: Yang, Wenrui, et al.
Publicado: (2023)

PB2049: THE EFFICACY OF HETROMBOPAG PLUS CYCLOSPORINE A IN PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A PROSPECTIVE REGISTRY STUDY
por: Gong, Yuemin, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
por: Zhao, Yufei, et al.
Publicado: (2023)

P792: CLINICAL STUDY OF HETROMBOPAG COMBINED WITH CYCLOSPORINE A IN THE TREATMENT OF CHILDREN WITH NON-SEVERE APLASTIC ANEMIA
por: Chang, Lixian, et al.
Publicado: (2023)

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis
por: Zhu, Yangmin, et al.
Publicado: (2020)

A multicentre trial of intensive immunosuppressive therapy combined with umbilical cord blood for the treatment of severe aplastic anaemia
por: Zhou, Fang, et al.
Publicado: (2022)

Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
por: Liu, Limin, et al.
Publicado: (2022)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

Predictive value of T cell receptor repertoire profiling for immunosuppressive therapy in severe aplastic anemia
por: Chen, Cunte, et al.
Publicado: (2023)

Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation
por: Liu, Limin, et al.
Publicado: (2021)

Aplastic anemia: immunosuppressive therapy in 2010
por: Risitano, Antonio M., et al.
Publicado: (2011)

Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia
por: Dong, Peiyuan, et al.
Publicado: (2022)

Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study
por: Yang, Wenrui, et al.
Publicado: (2023)

Pre-Transplant Platelet Refractoriness and Alternative Donors Are Associated With Cytomegalovirus Retinitis in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia
por: Zhang, Yuehong, et al.
Publicado: (2022)

Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis−associated aplastic anemia
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

Immunosuppressive Treatment in Children with Acquired Aplastic Anemia
por: Yıldırmak, Yıldız, et al.
Publicado: (2012)

Association between human leukocyte antigen and immunosuppressive treatment outcomes in Chinese patients with aplastic anemia
por: Chen, Lingyun, et al.
Publicado: (2023)

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
por: Rogers, Zora R., et al.
Publicado: (2019)

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag
por: Li, Ruixin, et al.
Publicado: (2022)

Impaired immunosuppressive effect of bone marrow mesenchymal stem cell-derived exosomes on T cells in aplastic anemia
por: Wang, Shichong, et al.
Publicado: (2023)

Effective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study
por: Du, Yali, et al.
Publicado: (2020)

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
por: Li, Ning, et al.
Publicado: (2012)

Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic
por: Zhang, Yawen, et al.
Publicado: (2023)

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
por: Zaimoku, Yoshitaka, et al.
Publicado: (2021)

Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia
por: Chen, Hai-Fei, et al.
Publicado: (2014)

Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China
por: Zuo, Wei, et al.
Publicado: (2020)

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
por: Zhang, Zhuxin, et al.
Publicado: (2023)

Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia
por: Zhou, Fang, et al.
Publicado: (2011)

Thymoma followed by aplastic anemia - two different responses to immunosuppressive therapy
por: de Castro, Murilo Antunes, et al.
Publicado: (2011)

Efficacy and safety of avatrombopag in aplastic anemia patients with liver disease
por: Wang, Huaquan, et al.
Publicado: (2023)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

The Potential Association of Delayed T Lymphocyte Reconstitution Within Six Months Post-Transplantation With the Risk of Cytomegalovirus Retinitis in Severe Aplastic Anemia Recipients
por: Mo, Wenjian, et al.
Publicado: (2022)

Identification of potential pathogenic genes for severe aplastic anemia by whole‐exome sequencing
por: Zhang, Yang, et al.
Publicado: (2022)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
por: Mei, Heng, et al.
Publicado: (2021)

P763: EFFICACY AND SAFETY OF AVATROMBOPAG IN THE TREATMENT OF TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA
por: Zhang, Ting, et al.
Publicado: (2023)

Immunosuppressive Therapy in Patients with Aplastic Anemia: A Single-Center Retrospective Study
por: Jalaeikhoo, Hasan, et al.
Publicado: (2015)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
por: Goronkova, Olga, et al.
Publicado: (2022)

Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia
por: Liu, Xu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kh48cnsbaoraa57oberrpken6n